Crescent Biopharma Inc(CBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CBIO Crescent Biopharma Inc

Trading 12-11 14:19:08 EST

15.06

+0.57

+3.93%

High15.15	Low14.08	Vol63.77K
Open14.38	D1 Closing14.49	Amplitude7.38%
Mkt Cap209.22M	Tradable Cap69.46M	Total Shares13.89M
T/O944.58K	T/O Rate1.38%	Tradable Shares4.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CBIO","market":"US","secType":"STK","nameCN":"Crescent Biopharma Inc","latestPrice":15.06,"timestamp":1765480723506,"preClose":14.49,"halted":0,"volume":63770,"delay":0,"floatShares":4612100,"shares":13892516,"eps":-13.454129,"marketStatus":"Trading","change":0.57,"latestTime":"12-11 14:19:08 EST","open":14.38,"high":15.15,"low":14.08,"amount":944576.8636500001,"amplitude":0.073844,"askPrice":15.12,"askSize":5,"bidPrice":15,"bidSize":183,"shortable":3,"etf":0,"ttmEps":-13.454129,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1389330000000,"exchange":"NASDAQ","adjPreClose":14.49,"preHourTrading":{"tag":"盘前","latestPrice":14.0201,"preClose":14.49,"latestTime":"09:00 EST","volume":31,"amount":435.2588015,"timestamp":1765461619748},"postHourTrading":{"tag":"盘后","latestPrice":14.49,"preClose":14.49,"latestTime":"19:43 EST","volume":481,"amount":6843.3869,"timestamp":1765413783139},"volumeRatio":0.126885,"impliedVol":2.2495,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CBIO","defaultTab":"news","newsList":[{"id":"2590366553","title":"Fairmount Funds Management LLC Reports Acquisition of Common Shares of Crescent Biopharma Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590366553","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590366553?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:31","pubTimestamp":1765229466,"startTime":"0","endTime":"0","summary":"Fairmount Funds Management LLC, as a beneficial owner, reported the acquisition of common shares of Crescent Biopharma Inc. . The Form 4 was filed by more than one reporting person, including Fairmount Funds Management LLC and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL3N2nRS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Fairmount Funds Management LLC Reports Acquisition of Common Shares of Crescent Biopharma Inc","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2589314834","title":"BUZZ-U.S. STOCKS ON THE MOVE-Raymond James, CAVA, Paramount Skydance","url":"https://stock-news.laohu8.com/highlight/detail?id=2589314834","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589314834?lang=en_us&edition=fundamental","pubTime":"2025-12-05 03:04","pubTimestamp":1764875069,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Raymond James, CAVA, Paramount SkydanceEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL6N3XA0L6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRL","CAVA","CBIO","GCO","LU0157215616.USD","LU0823434740.USD","IE0009356076.USD","FCX","MA","GWRE","PPG","NI","HL","CVX","GEV","PSKY","AXGN","BBW","CURV","V","LU0426412945.USD","FIVE","FISV","KR","XYZ","ULS","BK4077","BETA","TOL","SCCO","RJF","SNCR","HYNE","CDE","DG","MDU","AI","LKQ","DCI","IE00BQXX3C00.GBP","LEN","ARE"],"gpt_icon":1},{"id":"2589836664","title":"What's Happening With Crescent Biopharma Stock Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589836664","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589836664?lang=en_us&edition=fundamental","pubTime":"2025-12-05 00:29","pubTimestamp":1764865740,"startTime":"0","endTime":"0","summary":"Cresent Biopharma shares were trading higher Thursday but have since reversed and begun trading lower after the company announced a partnership with Sichuan Kelun-Biotech Biopharmaceutical.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/04/medical.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/04/medical.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49212844/whats-happening-with-crescent-biopharma-stock-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49212844/whats-happening-with-crescent-biopharma-stock-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2588560881","title":"Crescent Biopharma Shares Jump 18% Premarket After Cancer Drug Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2588560881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588560881?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:28","pubTimestamp":1764851313,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL4N3XA0W6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2588888137","title":"BUZZ-Crescent Biopharma jumps after cancer drug partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2588888137","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588888137?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:24","pubTimestamp":1764851056,"startTime":"0","endTime":"0","summary":"BUZZ-Crescent Biopharma jumps after cancer drug partnership ** Shares of drugmaker Crescent Biopharma CBIO.O rise 36.5% to $18.30 premarket ** Co says it has formed an exclusive partnership with China's Kelun-Biotech to develop and market new cancer treatments** Co is also raising $185 million from investors to fund clinical trials - CBIO** Says deal gives Kelun-Biotech rights to co's experimental drug CR-001 in Greater China** CBIO's CR-001 aims to boost immune response and block blood supply to tumors; SKB105 targets solid tumors, co says** Both firms plan to test drugs alone and in combination; human trials for 3 drugs set for 2026, co says** Up to last close, stock was down ~46% YTD   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL4N3XA0UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","BK7508","BK4139","CBIO","BK0060","BK0239","06990","BK1161","IVX.AU","LU0196878994.USD","LU1064130708.USD","BK7096","LU1934453819.USD","002422","LU1979443071.USD","BK7509","LU2148510915.USD"],"gpt_icon":0},{"id":"2588886694","title":"Crescent Biopharma Raises $185 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886694","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886694?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:37","pubTimestamp":1764848225,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc. has announced a private placement of approximately $185 million in securities to institutional and accredited investors. The offering, which is expected to close around December 8, 2025, was not registered under the Securities Act of 1933 and involves the sale of shares and pre-funded warrants. Investors participating in the placement include Forbion, Fairmount, Vestal Point Capital, BVF Partners, ADAR1, Balyasny Asset Management, and Venrock Healthcare Capital Partners. The company plans to use the proceeds to advance its clinical and preclinical programs and for general corporate purposes, with an expected cash runway into 2028. Jefferies, TD Cowen, Guggenheim Securities, Cantor, and Wedbush & Co. served as placement agents, and Piper Sandler acted as financial advisor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL2X3jBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","BK4127","CBIO","BK4139"],"gpt_icon":0},{"id":"2588886686","title":"Crescent Biopharma Announces Transformational Partnership With Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886686?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:35","pubTimestamp":1764848100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUABHXCP2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2588588664","title":"Crescent Biopharma Inc - on Track to Start Global Phase 1/2 Clinical Trial of Cr-001 in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588588664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588588664?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:35","pubTimestamp":1764848100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUABHXCP2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2588868458","title":"Crescent Biopharma and Kelun-Biotech Launch Strategic Oncology Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2588868458","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588868458?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847814,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc. has announced a strategic partnership with Kelun-Biotech to jointly develop and commercialize novel oncology therapeutics. Under the terms of the collaboration, Crescent has granted Kelun-Biotech exclusive rights to research, develop, manufacture, and commercialize CR-001, a PD-1 x VEGF bispecific antibody, in Greater China, while Crescent has received exclusive rights to develop and commercialize SKB105, an integrin beta-6-directed antibody-drug conjugate , in the United States, Europe, and other markets outside Greater China. The partnership aims to advance both drug candidates as monotherapies and in combination, with both expected to enter Phase 1/2 clinical trials in early 2026. The collaboration is designed to accelerate development and maximize the potential of these therapies for cancer treatment globally.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4ZhvgN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002422","IE00BGHQF748.EUR","BK4139","LU2095319765.USD","BK0239","LU0314104364.USD","LU1064130708.USD","BK4585","LU1064131003.USD","LU2148510915.USD","BK4588","LU2210149790.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU1979443071.USD","LU2210150020.SGD","06990","BK0060","IE00BKPKM429.USD","LU0196878994.USD","NDAQ","LU1934453819.USD","BK1161","CBIO","BK4112"],"gpt_icon":0},{"id":"2588886556","title":"Crescent Biopharma Inc - Kelun-Biotech Eligible for Milestones up to $1.25 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886556?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["002422","BK0239","BK4139","LU1979443071.USD","06990","LU1064130708.USD","LU1934453819.USD","LU0196878994.USD","BK1161","BK0060","LU2148510915.USD","LU1064131003.USD","CBIO"],"gpt_icon":0},{"id":"2588886348","title":"Crescent Biopharma Inc - Cr-001 and Skb105 to Enter Phase 1/2 Trials in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886348?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2588886301","title":"Crescent Biopharma Inc - Co to Receive $20 Mln Upfront Payment,Additional Milestones of up to US$30 Mln From Kelun-Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886301?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","LU0196878994.USD","LU1979443071.USD","CBIO","LU1934453819.USD","LU1064130708.USD","06990","LU1064131003.USD","BK4139","BK0060","LU2148510915.USD","002422","BK1161"],"gpt_icon":0},{"id":"2588886300","title":"Crescent Biopharma Inc - Kelun-Biotech to Receive $80 Mln Upfront Payment,Additional Milestones of up to US$1.25 Billion From Crescent","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886300?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1064130708.USD","BK1161","002422","LU1064131003.USD","LU1934453819.USD","LU2148510915.USD","LU0196878994.USD","LU1979443071.USD","BK0060","06990","CBIO","BK4139","BK0239"],"gpt_icon":0},{"id":"2588885002","title":"Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588885002","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588885002?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["002422","CBIO","LU1064130708.USD","BK1161","LU1934453819.USD","BK0060","06990","BK0239","LU1979443071.USD","LU0196878994.USD","LU1064131003.USD","BK4139","LU2148510915.USD"],"gpt_icon":0},{"id":"2581885420","title":"Crescent Biopharma Inc  expected to post a loss of $2.02 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581885420","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581885420?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:50","pubTimestamp":1762523404,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc  expected to post a loss of $2.02 a share - Earnings Preview Crescent Biopharma Inc CBIO.OQ CBIO.O is expected to  show no change in quarterly revenue when it reports  results  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ1RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2581060631","title":"Crescent Biopharma posts $24.6 million net loss on $20.3 million R&D expenses in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581060631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581060631?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:31","pubTimestamp":1762432277,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc. reported a net loss of $24.6 million, or $1.27 per basic and diluted share, for the third quarter ended September 30, 2025. Research and development expenses were $20.3 million, while general and administrative expenses totaled $5.5 million for the quarter. The company held cash of $133.3 million as of September 30, 2025, which is expected to fund operations through 2027. As of the end of the quarter, Crescent Biopharma had approximately 19.6 million shares outstanding, including equivalents. During the period, Crescent advanced its oncology pipeline, with an IND submission for CR-001, a PD-1 x VEGF bispecific antibody, on track for the fourth quarter of 2025, aiming to start a global Phase 1 trial in early 2026. An IND submission for CR-002, a novel antibody-drug conjugate, is planned for mid-2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLJJgQy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","CBIO","BK4139","BK4585","BK4112","BK4588"],"gpt_icon":0},{"id":"2581436060","title":"Crescent Biopharma: Cash Was $133.3 Mln as of September 30, Anticipated to Fund Operations Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581436060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581436060?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUABNVB8C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2581106044","title":"Crescent Biopharma: Qtrly Loss per Share Attributable to Ordinary Shareholders $-1.27","url":"https://stock-news.laohu8.com/highlight/detail?id=2581106044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581106044?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUABNVB8C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2581722806","title":"Crescent Biopharma to Present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722806","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722806?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345819,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc., a biotechnology company focused on advancing cancer therapies, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, in London. A live webcast of the presentation will be available on the company's investor website, with a replay accessible for 90 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL6BBr3C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","LU2210149790.SGD","CBIO","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2580730358","title":"Crescent Biopharma Unveils Preclinical Data for CR-001 PD-1 x VEGF Bispecific Antibody Ahead of Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2580730358","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580730358?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:05","pubTimestamp":1762265119,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc. announced that preclinical data for its investigational drug candidate CR-001, a tetravalent bispecific antibody targeting PD-1 and VEGF for the treatment of solid tumors, will be presented at the Society for Immunotherapy of Cancer's  40th Annual Meeting, scheduled for November 7-9, 2025. According to the company, CR-001 demonstrated cooperative pharmacology and robust anti-tumor activity in preclinical models, with increased T-cell activation and tumor growth reduction. An Investigational New Drug  submission is planned for the fourth quarter of 2025 to support the initiation of a global Phase 1 clinical trial in patients with solid tumors in the first quarter of 2026. The abstract is available on SITC's website, and the poster presentation will be accessible on Crescent's website on the day of the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL6dGjKr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","BK4585","IE00BGHQF748.EUR","BK4588","BK4139","BK4112","IE00BKPKM429.USD","CBIO","LU2095319765.USD","IE00B3QW5Z07.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.glycomimetics.com","stockEarnings":[{"period":"1week","weight":0.0805},{"period":"1month","weight":0.1053},{"period":"3month","weight":0.1546},{"period":"6month","weight":-0.0771},{"period":"1year","weight":-0.5053},{"period":"ytd","weight":-0.4181}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.019108},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.015525},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.053963},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.063712},{"month":5,"riseRate":0.5,"avgChangeRate":0.092337},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022838},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058163},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.053488},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.058271},{"month":10,"riseRate":0.5,"avgChangeRate":0.107936},{"month":11,"riseRate":0.75,"avgChangeRate":0.290074},{"month":12,"riseRate":0.25,"avgChangeRate":-0.015654}],"exchange":"NASDAQ","name":"Crescent Biopharma Inc","nameEN":"Crescent Biopharma Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Crescent Biopharma Inc(CBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Crescent Biopharma Inc(CBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Crescent Biopharma Inc,CBIO,Crescent Biopharma Inc股票,Crescent Biopharma Inc股票老虎,Crescent Biopharma Inc股票老虎国际,Crescent Biopharma Inc行情,Crescent Biopharma Inc股票行情,Crescent Biopharma Inc股价,Crescent Biopharma Inc股市,Crescent Biopharma Inc股票价格,Crescent Biopharma Inc股票交易,Crescent Biopharma Inc股票购买,Crescent Biopharma Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Crescent Biopharma Inc(CBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Crescent Biopharma Inc(CBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction